Avinger CE marks Wildcat for PAD
This article was originally published in Clinica
US medtech firm Avinger has CE marked its Wildcat catheter for sale in Europe. The device is intended for use in endovascular procedures for the treatment of peripheral artery disease (PAD), by creating a channel in blocked peripheral vessels. It may also be used to aid placement of conventional guidewires beyond stenotic lesions, prior to percutaneous intervention. Avinger will start selling the catheter in some European countries by the end of the second quarter of 2011. Wildcat is available in the US as a guidewire support catheter. Avinger (Redwood City, California) is conducting an 88-patient study, CONNECT, evaluating Wildcat for crossing chronic total occlusions in femoropopliteal lesions, in the US. Initial results are expected next week.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.